One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes
Article Information
vol. 53 no. 5 1187-1194
PubMed
Published By
Print ISSN
Online ISSN
History
- January 23, 2004
- October 14, 2003
- Published in print April 26, 2004.
Copyright & Usage
DIABETES
Author Information
- Kristine B. Degn1,
- Claus B. Juhl1,
- Jeppe Sturis2,
- Grethe Jakobsen2,
- Birgitte Brock1,
- Visvanathan Chandramouli3,
- Joergen Rungby1,
- Bernard R. Landau3 and
- Ole Schmitz1
- 1Department of Endocrinology (M & C), University Hospital of Aarhus, and Department of Clinical Pharmacology, University of Aarhus, Aarhus, Denmark
- 2Novo Nordisk A/S, Bagsværd, Denmark
- 3Case Western Reserve University School of Medicine, Cleveland, Ohio
- Address correspondencereprint requests to Ole Schmitz, MD, Department of Medicine M (Endocrinology & Diabetes), University Hospital of Aarhus, AKH, Nørrebrogade 42-44 DK-8000 Aarhus C, Denmark. E-mail: ole.schmitz{at}iekf.au.dk